PADT Found Not to Improve Survival

Share this content:

Primary androgen deprivation  therapy (PADT) is not associated with improved 10-year survival in elderly men with localized prostate cancer when compared with conservative management, according to a study published in The Journal of the American Medical Association (2008;300:173-181).

PADT was associated with a lower 10-year prostate cancer-specific survival.

The study included 19,271 men (median age 77 years), of whom 7,867 received PADT and 11,404 were managed conservatively.

You must be a registered member of Renal and Urology News to post a comment.